+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Role of the endothelin system in sexual dimorphism in cardiovascular and renal diseases



Role of the endothelin system in sexual dimorphism in cardiovascular and renal diseases



Life Sciences 159: 20-29



Epidemiological studies of blood pressure in men and women and in experimental animal models point to substantial sex differences in the occurrence of arterial hypertension as well as in the various manifestations of arterial hypertension, including myocardial infarction, stroke, retinopathy, chronic kidney failure, as well as hypertension-associated diseases (e.g. diabetes mellitus). Increasing evidence demonstrates that the endothelin (ET) system is a major player in the genesis of sex differences in cardiovascular and renal physiology and diseases. Sex differences in the ET system have been described in the vasculature, heart and kidney of humans and experimental animals. In the current review, we briefly describe the role of the ET system in the cardiovascular and renal systems. We also update information on sex differences at different levels of the ET system including synthesis, circulating and tissue levels, receptors, signaling pathways, ET actions, and responses to antagonists in different organs that contribute to blood pressure regulation. Knowledge of the mechanisms underlying sex differences in arterial hypertension can impact therapeutic strategies. Sex-targeted and/or sex-tailored approaches may improve treatment of cardiovascular and renal diseases.

(PDF emailed within 0-6 h: $19.90)

Accession: 058791313

Download citation: RISBibTeXText

PMID: 26939577

DOI: 10.1016/j.lfs.2016.02.093


Related references

Sexual dimorphism in renal ischemia-reperfusion injury in rats: possible role of endothelin. Kidney International 62(4): 1364-1371, 2002

Role of endothelin in the pathogenesis of renal and cardiovascular diseases. Polskie Archiwum Medycyny Wewnetrznej 88(5): 330-335, 1992

Physiological role of he endothelin system in human cardiovascular and renal haemodynamics. Current Opinion in Nephrology & Hypertension 6(1): 69-73, 1997

Physiological role of the endothelin system in human cardiovascular and renal haemodynamics. Current Opinion in Nephrology and Hypertension 6(1): 69-73, 1997

Sexual dimorphism in body fat distribution and risk for cardiovascular diseases. Journal of Cardiovascular Translational Research 2(3): 321-327, 2010

Endothelin and endothelin antagonists: Potential role in cardiovascular and renal disease. Molecular and Cellular Biochemistry 157(1-2): 259-267, 1996

Potential role of endothelin-1 and endothelin antagonists in cardiovascular diseases. Basic Research in Cardiology 95(4): 290-298, August, 2000

Physiological and pathophysiological role of endothelin-endothelin receptors system in cardiovascular system. Nihon Rinsho. Japanese Journal of Clinical Medicine 51(6): 1540-1547, 1993

GPCRs in context: sexual dimorphism in the cardiovascular system. British Journal of Pharmacology 175(21): 4047-4059, 2018

Endothelin in renal diseases and cardiovascular remodeling in renal failure. Internal Medicine 40(4): 285-291, 2001

Role of renin-angiotensin system in cardiovascular and renal diseases. Japanese Journal of Pharmacology 71(SUPPL 1): 56P, 1996

Role of the renin-angiotensin system in cardiovascular and renal diseases. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 109(5): 223-233, 1997

Changes in renal hemodynamics and structure in the aging kidney; sexual dimorphism and the nitric oxide system. Experimental Gerontology 40(4): 271-278, 2005

Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Current Opinion in Nephrology & Hypertension 11(1): 59-66, 2002

Proinflammatory effects of angiotensin II and endothelin: targets for progression of cardiovascular and renal diseases. Current Opinion in Nephrology and Hypertension 11(1): 59-66, 2001